TradingMenu expanded
Forge Markets Browse Companies
DataMenu expanded
Forge Data IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Reports Private Market Data & Analytics Startup News
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Browse Companies
Data Menu expandedData
Forge Data
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Reports
Private Market Data & Analytics
Startup News
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Companies / Nkarta Therapeutics Stock

Nkarta Therapeutics Stock

nkartatx.comHealthcareFounded: 2015Funding to Date: $125MM

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic natural killer (NK) cell therapies for cancer.

Learn more about Nkarta Therapeutics IPO
Register for Details

For more details on financing and valuation for Nkarta Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Nkarta Therapeutics.

Register Today

Team

Management Team

Paul Hastings
Founder, Chief Executive Officer & Board Member
Matthew Plunkett Ph.D
Chief Financial Officer and Senior Vice President
Dario Campana MD
Scientific Founder
Kanya Rajangam Ph.D
Chief Medical Officer and Senior Vice President
James Trager Ph.D
Senior Vice President and Chief Scientific Officer

Board Members

Jill Carroll
SR One
Michael Dybbs Ph.D
Samsara BioCapital
Fouad Azzam Ph.D
Life Sciences Partners
Paul Hastings
Ali Behbahani MD
New Enterprise Associates
Tiba Aynechi Ph.D
Novo Holdings

Other companies like Nkarta Therapeutics in the Healthcare sector

Neuralink
Sector
Healthcare
Last Round Est. Valuation
$2.15B
Colossal Biosciences
Sector
Healthcare
 
 
Altos Labs
Sector
Healthcare
Last Round Est. Valuation
$3.67B
Synchron
Sector
Healthcare
Last Round Est. Valuation
$400.53MM
Grail
Sector
Healthcare
Last Round Est. Valuation
$4.26B
OURA
Sector
Healthcare
 
 
Cytonics
Sector
Healthcare
 
 
Mammoth Biosciences
Sector
Healthcare
Last Round Est. Valuation
$1.08B
Precision Neuroscience
Sector
Healthcare
 
 

News

BioSpace 12/09/2019
Nkarta Therapeutics Expands Senior Management Team with Key Hires in Finance and Clinical Development | BioSpace
Nkarta Therapeutics Expands Senior Management Team with Key Hires in Finance and Clinical Development - read this article along with other careers information, tips and advice on BioSpace
Pulse 2.0 09/11/2019
Biopharmaceutical Company Nkarta Therapeutics Raises $114 Million
Nkarta Therapeutics announced it has raised $114 million in Series B funding led by new investor Samsara BioCapital.

Trending Companies

Frequently Asked Questions